Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined
real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with …

Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines
recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke …

Cardiovascular disease is an emerging medical issue in patients with hemophilia (PWH)
and its prevalence is increasing up to 15% in PWH in the United States. Atrial fibrillation …

Purpose Elevated bilirubin levels have been associated with major depressive disorder
(MDD); however, the exact impact of bilirubin on MDD and the underlying molecular …

Background Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic
events in patients with cardiovascular diseases. The most common VKA are warfarin and …

Background We previously reported that standard deviation (SD) of systolic blood pressure
(SBP), an index of BP variability, and SBP-time in target range (TTR), an index of BP …

Background Direct oral anticoagulants (DOACs) are increasingly replacing vitamin K
antagonists (VKA) for clinical indications requiring long-term oral anticoagulation. In contrast …

Here, we summarize the European Hematology Association-International Society on
Thrombosis and Haemostasis-European Association for Hemophilia and Allied Disorders …

The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring,
however emergency measurements are gaining importance. Current assays feature good …